Literature DB >> 11507336

Corneal neovascularization.

J H Chang1, E E Gabison, T Kato, D T Azar.   

Abstract

Corneal neovascularization (NV) is a sight-threatening condition usually associated with inflammatory or infectious disorders of the ocular surface. It has been shown in the field of cancer angiogenesis research that a balance exists between angiogenic factors (such as fibroblast growth factor and vascular endothelial growth factor) and anti-angiogenic molecules (such as angiostatin, endostatin, or pigment epithelium derived factor) in the cornea. Several inflammatory, infectious, degenerative, and traumatic disorders are associated with corneal NV, in which the balance is tilted towards angiogenesis. The pathogenesis of corneal NV may be influenced by matrix metalloproteinases and other proteolytic enzymes. New medical and surgical treatments, including angiostatic steroids, nonsteroidal inflammatory agents, argon laser photocoagulation, and photodynamic therapy have been effective in animal models to inhibit corneal NV and transiently restore corneal "angiogenic privilege."

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507336     DOI: 10.1097/00055735-200108000-00002

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  186 in total

1.  Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.

Authors:  Iva Dekaris; Nikica Gabrić; Nataša Drača; Maja Pauk-Gulić; Neven Miličić
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

2.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

Review 3.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 4.  Wound healing fibroblasts modulate corneal angiogenic privilege: interplay of basic fibroblast growth factor and matrix metalloproteinases in corneal angiogenesis.

Authors:  Jin-Hong Chang; Kyu Yeon Han; Dimitri T Azar
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

5.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

6.  Eyes wide s-flt: clearly, avascular fidelity is a vascular endothelial growth factor family affair.

Authors:  Royce Mohan
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

7.  Ultrastructural pathology of corneal neovascularization after photodynamic therapy in rabbits.

Authors:  Hong Chen; Ming-Chang Zhang; Zhi Wang; Ying Zhang
Journal:  Int J Ophthalmol       Date:  2010-12-18       Impact factor: 1.779

8.  Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.

Authors:  Yasin Yücel Bucak; Mesut Erdurmus; Elçin Hakan Terzi; Aysel Kükner; Serdal Çelebi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-19       Impact factor: 3.117

9.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries.

Authors:  Neera Tewari-Singh; Anil K Jain; Swetha Inturi; David A Ammar; Chapla Agarwal; Puneet Tyagi; Uday B Kompella; Robert W Enzenauer; J Mark Petrash; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-24       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.